| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID1629: Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma |
|
Medicine details |
|
| Medicine name | nivolumab (Opdivo®) |
| Formulation | concentrate for solution for infusion |
| Reference number | 5029 |
| Indication | In combination with ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1% |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/03/2023 |
| NICE guidance | |